Patient-controlled methylphenidate for the management of fatigue in patients with advanced cancer: A preliminary report
Patient-controlled methylphenidate for the management of fatigue in patients with advanced cancer: A preliminary report
复制标题
DOI：
10.1200/jco.2003.06.156
复制
发表时间：
2003-12-01
影响因子：
45.3
通讯作者：
Escalante, C
中科院分区：
文献类型：
--
作者：
Bruera, E;Driver, L;Escalante, C
目的：为了评估患者控制的哌醋甲酯cancer-related fatigue.Patients和方法的影响：在这项前瞻性开放研究中，31例晚期癌症和疲劳谁得分大于或等于4的规模为0至10哌醋甲酯5毫克口服每2小时需要7天（最大，20毫克/天）。每天评估多种症状;主要终点疲劳使用0 - 10量表测量，并在基线、第7天和第28天进行慢性疾病治疗疲劳功能评估（FACIT-F）。30名可评估患者的（+/-标准差）评分在基线和第7天之间显著改善：疲劳（0 - 10分），7.2 +/- 1.6 vs 3.0 +/- 1.9（P
Purpose: To assess the effects of patient-controlled methylphenidate for cancer-related fatigue.Patients and Methods: In this prospective open study, 31 patients with advanced cancer and fatigue who scored greater than or equal to 4 on a scale of 0 to 10 received methylphenidate 5 mg by mouth every 2 hours as needed for 7 days (maximum, 20 mg/d). Multiple symptoms were assessed daily; the primary end point, fatigue, was measured using the 0 to 10 scale, and the Functional Assessment for Chronic Illness Therapy-Fatigue (FACIT-F) was performed at baseline, day 7, and day 28.Results: The following mean (+/- standard deviation) scores for 30 assessable patients improved significantly between baseline and day 7: fatigue (0 to 10 scale), 7.2 +/- 1.6 v 3.0 +/- 1.9 (P